Attend the FierceBiotech Executive Breakfast at BIO 2019
Join us on June 5th for our panel discussion on real-world evidence. Reserve your seat today.
Pharma’s reputation is holding steady with patient groups with an annual study finding 41% giving pharma good marks, similar to 43% the year before.
Allergan’s digital booking platform for aesthetic treatments helps consumers find Allergan-branded medical aesthetics but also regular spa services.
Gilead Sciences launched its first national TV campaign for HIV treatment Biktarvy featuring a broad range of different people living with HIV.
Klick Health debuts its book of the best practices, processes, tools and insights it uses to build adaptive brands for pharma marketers.
Evenity's annual price of $21,900 is on par with that of Radius' rival med Tymlos. But its safety and clinical efficacy profile might hurt uptake.
Look out, Roche and Regeneron. Thanks to an FDA priority review, Novartis eye candidate brolucizumab could start stealing sales in October.
Pharmaceutical ad spending continued its upward climb last year, with spending topping $6.46 billion, according to Kantar Media.
Clovis Oncology's PARP inhibitor Rubraca didn't spur enough response to warrant continuing a phase 2 bladder cancer study.
Boehringer Ingelheim talks about its winning strategy for IPF treatment Ofev as the winner of #FierceMadness DTC 2019.
Thanks to a new FDA green light, Keytruda is allowed in patients with low PD-L1 levels, but analysts have expressed doubts about its real-world use.